Quadruple intervention against tuberculosis.

Tuberculosis treatment currently demands a six-month course of antibiotics, and this project tests whether a quadruple strategy—combining a shorter drug regime, vitamin D correction, a new vaccine, and early HIV therapy—can cut that time to one month and prevent new infections. Why this matters: Latent TB, where the bacterium lies dormant in the body, affects roughly a quarter of the world’s population. The standard six-month preventive treatment is often not completed, and vitamin D deficiency is common in TB patients, potentially weakening immune defences. HIV co-infection further complicates control. The research addresses these interconnected gaps by testing each intervention in parallel: a shorter drug regime, vitamin D supplementation, a novel vaccine combined with latent TB treatment, and early antiretroviral therapy in HIV-positive individuals. Potential impact: If successful, the work could transform TB control by making preventive treatment far more practical—reducing dropout rates, boosting immune responses, and cutting transmission. This would directly affect public health systems in high-burden settings, where TB remains a leading infectious killer, and could reduce the need for lengthy clinic visits and monitoring. The vaccine component, if effective, might also provide lasting protection beyond treatment. The project is applied and intervention-focused, with clear pathways to clinical implementation.